全文获取类型
收费全文 | 168266篇 |
免费 | 7847篇 |
国内免费 | 1161篇 |
专业分类
耳鼻咽喉 | 2008篇 |
儿科学 | 7022篇 |
妇产科学 | 3232篇 |
基础医学 | 17618篇 |
口腔科学 | 6034篇 |
临床医学 | 11635篇 |
内科学 | 35601篇 |
皮肤病学 | 3654篇 |
神经病学 | 12156篇 |
特种医学 | 6812篇 |
外国民族医学 | 3篇 |
外科学 | 34502篇 |
综合类 | 5331篇 |
现状与发展 | 2篇 |
一般理论 | 5篇 |
预防医学 | 10547篇 |
眼科学 | 3356篇 |
药学 | 9178篇 |
18篇 | |
中国医学 | 3455篇 |
肿瘤学 | 5105篇 |
出版年
2023年 | 3954篇 |
2022年 | 5060篇 |
2021年 | 7469篇 |
2020年 | 5427篇 |
2019年 | 15019篇 |
2018年 | 12271篇 |
2017年 | 6981篇 |
2016年 | 2406篇 |
2015年 | 2990篇 |
2014年 | 4382篇 |
2013年 | 3327篇 |
2012年 | 2371篇 |
2011年 | 6009篇 |
2010年 | 2719篇 |
2009年 | 2878篇 |
2008年 | 2922篇 |
2007年 | 2386篇 |
2006年 | 2039篇 |
2005年 | 2398篇 |
2004年 | 2258篇 |
2003年 | 1776篇 |
2002年 | 2175篇 |
2001年 | 2592篇 |
2000年 | 3489篇 |
1999年 | 3778篇 |
1998年 | 3426篇 |
1997年 | 2445篇 |
1996年 | 1682篇 |
1995年 | 1195篇 |
1994年 | 1225篇 |
1993年 | 873篇 |
1992年 | 907篇 |
1991年 | 752篇 |
1990年 | 740篇 |
1989年 | 551篇 |
1988年 | 580篇 |
1987年 | 406篇 |
1985年 | 4677篇 |
1984年 | 6596篇 |
1983年 | 5160篇 |
1982年 | 5665篇 |
1981年 | 5166篇 |
1980年 | 4485篇 |
1979年 | 4474篇 |
1978年 | 3587篇 |
1977年 | 2714篇 |
1976年 | 3233篇 |
1975年 | 2579篇 |
1974年 | 2251篇 |
1973年 | 2120篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
David A. Hughes Graham C. Smith Joyce E. Davidson Anna V. Murphy T. James Beattie 《Pediatric nephrology (Berlin, Germany)》1996,10(4):445-447
. Neutrophil-mediated tissue damage has been implicated in the pathogenesis of diarrhoea-associated haemolytic uraemic syndrome
(D+ HUS). This study evaluates priming and activation of the neutrophil oxidative burst in D+ HUS using chemiluminescent techniques.
Peripheral blood neutrophils from 11 children with acute D+ HUS were examined. No difference was found in the oxidative burst
of neutrophils from patients and controls. Serum elastase levels were measured in 8 patients and found to be significantly
elevated. Although elastase results suggest neutrophil activation, chemiluminescence studies do not confirm this in the peripheral
blood neutrophil. This does not support a significant role for circulating agents in priming and activating the peripheral
blood neutrophil.
Received August 17, 1995; received in revised form and accepted November 27, 1995 相似文献
72.
R. P. Heaney T. M. Zizic I. Fogelman W. P. Olszynski P. Geusens C. Kasibhatla N. Alsayed G. Isaia M. W. Davie C. H. Chesnut III 《Osteoporosis international》2002,13(6):501-505
Risedronate treatment reduces the risk of vertebral fracture in women with existing vertebral fractures, but its efficacy
in prevention of the first vertebral fracture in women with osteoporosis but without vertebral fractures has not been determined.
We examined the risk of first vertebral fracture in postmenopausal women who were enrolled in four placebo-controlled clinical
trials of risedronate and who had low lumbar spine bone mineral density (BMD) (mean T-score =–3.3) and no vertebral fractures at baseline. Subjects received risedronate 5 mg (n= 328) or placebo (n= 312) daily for up to 3 years; all subjects were given calcium (1000 mg daily), as well as vitamin D supplementation (up
to 500 IU daily) if baseline serum 25-hydroxyvitamin D levels were low. The incidence of first vertebral fracture was 9.4%
in the women treated with placebo and 2.6% in those treated with risedronate 5 mg (risk reduction of 75%, 95% confidence interval
37% to 90%; P= 0.002). The number of patients who would need to be treated to prevent one new vertebral fracture is 15. When subjects were
stratified by age, similar significant reductions were observed in patients with a mean age of 64 years (risk reduction of
70%, 95% CI 8% to 90%; P= 0.030) and in those with a mean age of 76 years (risk reduction of 80%, 95% CI 7% to 96%; P= 0.024). Risedronate treatment therefore significantly reduces the risk of first vertebral fracture in postmenopausal women
with osteoporosis, with a similar magnitude of effect early and late after the menopause.
Received: 12 September 2001 / Accepted: 11 December 2001 相似文献
73.
A new range of stand magnifiers has been released by the COIL company in the United Kingdom. Examination of these magnifiers reveals that they fail to deliver the rated magnifications labelled prominently on the appliances, as a result of the manufacturer's conformance with the requirements of the German DIN standard and the use of back vertex power (F'v) rather than equivalent dioptric power (Fm) of the magnifier. In this study we provide information on the optometric parameters of these new stand magnifiers that will assist the more accurate specification of improvements in vision expected from their use. 相似文献
74.
目的:了解改水降氟后地氟病的防治效果。方法:水氟,尿氟测定均为电极法,氟斑牙诊断为Dean‘s法。结果:该村自1985年改饮低氟水,水氟含量由改水前的6.05mg/L降至改水后的0.48mg/L。改水后未出现新的氟骨症患者,8-12岁儿童氟斑牙患病率呈逐年下降趋势,改水后7-15年间氟斑牙病率均已稳定,表明病情得到有效控制,且达到稳定控制状态,结论:坚持长年饮用低氟水,地方性氟中毒就能得到有效控制。 相似文献
75.
Prevention of Bone Loss by Clodronate in Early Postmenopausal Women with Vertebral Osteopenia: A Dose-Finding Study 总被引:1,自引:0,他引:1
M. J. V?lim?ki K. Laitinen K. Laitinen A. Patronen H. Puolijoki H. Puolijoki J. Sepp?nen L. Pylkk?nenand the Probone Study Group 《Osteoporosis international》2002,13(12):937-947
This double-masked, placebo-controlled study was undertaken to determine the efficacy and safety of oral clodronate in the
prevention of bone loss in early postmenopausal women with vertebral osteopenia. Altogether 610 women with a mean age of 53
years were recruited for the study. They were 1–5 years postmenopausal and their lumbar spine bone mineral density (BMD) was
at least 1 standard deviation below the mean of premenopausal women (T-score ≤−1). The subjects were randomized into five study groups to receive either placebo, clodronate 65 mg, 400 mg or 800
mg daily, or intermittent clodronate in 3 month cycles with 400 mg daily for 15 days followed with no treatment for 75 days
for 3 years. One hundred and eighty-seven of 509 women who completed the primary study continued in the extension study of
2 years in which previous placebo users were switched to clodronate 800 mg daily, while previous users of 400 mg or 800 mg
of clodronate used either placebo or 800 mg of clodronate daily. In the primary study clodronate was administered in the evening,
and in the extension 1 h before breakfast on an empty stomach. In the primary study mean changes in lumbar spine BMD were
−3.4% in the placebo group and +0.4% in 800 mg clodronate group [difference between groups at 3 years 3.8% (95% CI 2.7% to
4.9%, p<0.0001)], and in the trochanter area BMD −1.1% in the placebo group, and + 0.4% in the 800 mg clodronate group [difference
between groups at 3 years 1.5% (95% CI 0.05% to 2.9%)]. During the extension study mean changes in lumbar spine BMD were +1.5%
in the clodronate group and −0.2 % in the placebo group [difference between groups 1.7% (CI 0.4% to 3.0%, p = 0.010)] and in trochanter BMD were +2.5% in the clodronate group and no change in the placebo group [difference between
groups 2.1% (CI 0.3% to 3.9%, p = 0.007)]. No statistically significant differences between the placebo and 800 mg clodronate groups were found in the femoral
neck BMD. In the primary study the urinary excretion of type I collagen aminoterminal telopeptide (NTX) decreased by 44% (p<0.0001 compared with placebo) and that of deoxypyridinoline by 18% (p<0.0001) in the clodronate 800 mg group. In the extension study urinary NTX decreased by 51% (p<0.0001) in those who were switched to 800 mg of clodronate and increased by 67% (p<0.0001) in those who stopped using that dose. There was no difference in the frequency of gastrointestinal complaints between
clodronate- and placebo-treated patients in the primary study, but they were more common among women who received clodronate
in the extension phase. Clodronate in daily doses of 400–800 mg caused a slight elevation of aminotransferase levels, usually
within the reference range. In bone biopsies no defect in mineralization was found. In conclusion, clodronate in a daily dose
of 800 mg prevents early postmenopausal bone loss at the sites of the skeleton in which cancellous bone predominates. It effectively
reduces bone resorption and bone turnover rate. Antifracture efficacy of clodronate remains to be established by prospective,
placebo-controlled trials.
Received: 4 March 2002 / Accepted: 9 July 2002 相似文献
76.
77.
78.
本文报道14例甲亢危象,其发病率为4.5%,其发病与感染、劳累、情绪激动及同位素治疗有关。指出同位素治疗甲亢初期应服用抗甲状腺药物,讨论了淡漠型危象的有关问题。 相似文献
79.
Inthistwoyears,westudiedonCVAofchronicpulmonaryheartdiseaseandpulmonaryheartdiseasepatients,andfoundmanyCVAindexofthesepatientswereabnormal,andwereinfluencedbymanyfactors.Thechangeofpulmonaryheartdiseaseasfollowing.1Subjectsandmethods1.1Subjects32caseswerefromin-patientsofourhospital,in-cluding30malesand2females,age64~82,averageage(72±8).Thediagnosisofpulmonaryheartdiseaseaccordedwiththecriteriainstitutedonthesecondpulmonaryheartdiseasespecialmeetingin1997… 相似文献
80.
The generation of thrombin-like activity from rat, human, bovine and mouse prothrombin by Echis carinatus venom (ECV) treatment was compared using a partially purified system (i.e. whole ECV and isolated prothrombin). A rapid increase in coagulant activity was obtained within 0.5 to 2 min., being constant upon further incubation for 60 min. A large variation in coagulant activity of the ECV generated thrombin from the four species was found, whereas no differences were found for the amidolytic activities. The coagulant activities of the ECV generated thrombin was also low compared with the corresponding thrombin activities obtained by physiological activation. Coagulant activity of the ECV generated thrombin levelled off at increasing concentration of prothrombin in the sample as measured by the one-stage coagulation assay. By measuring amidolytic activity a linear relationship to the concentration of prothrombin was found, however. These findings indicate that ECV converts prothrombin from the four different species to a thrombin-like protein with properties distinct from -thrombin. The lack of linearity in the ECV generated clot activity with increasing concentration of prothrombin could be explained by assuming a dimerization of the thrombin like protein molecules making them less accessible to fibrinogen. The significance of these observations for the quantification of prothrombin from different species is discussed. 相似文献